Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

80 results about "Cytosol" patented technology

The cytosol, also known as intracellular fluid (ICF) or cytoplasmic matrix, or groundplasm, is the liquid found inside cells. It is separated into compartments by membranes. For example, the mitochondrial matrix separates the mitochondrion into many compartments.

Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders

The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line with the latter aspect, disclosed herein are pharmaceutical compositions and advantageous components thereof that substantially enhance the effective delivery and release of a therapeutic nucleic acid into the right internal compartment of the muscle cell, such as the cytosol and / or the nucleus, in which compartment it can reach and act upon its genetic target. As disclosed herein, this substantially enhanced delivery and release is achieved by a provision of an endosomal-escape-enhancing saponin in the disclosed herein pharmaceutical compositions comprising therapeutic nucleic acids and, optionally, muscle cell-targeting ligands conjugated therewith. As for the first time demonstrated herein, these saponin types not only surprisingly retain their endosomal-escape-enhancing properties in fully differentiated muscle cells but also can in an unconjugated state successfully be delivered thereto together with the therapeutic nucleic acids.
Owner:SAPREME TECH BV

Polypeptide conjugates for intracellular delivery of nucleic acids

The present disclosure provides for polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a polyarginine peptide and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the polyarginine peptide. The present disclosure demonstrates that cCPPs conjugated to polyarginine peptides can be used to deliver nucleic acids to the cytosol of cells.
Owner:OHIO STATE INNOVATION FOUND

Peptide-based delivery agent with asparagine-containing mask peptide group and method of making and using the same

Disclosed herein is a delivery agent that facilitates effective delivery of drugs and other compounds across lipid layers. The delivery agent disclosed herein comprises an asparagine-containing mask peptide group comprising at least one asparagine amino acid moiety and which provides lipid solubility under selected conditions and aqueous solubility under other conditions, and can effectively deliver compounds into the cell cytosol.
Owner:ENDOREL BIOSCIENCES LLC

Peptide-based delivery agent and method of making and using the same

Disclosed herein is a delivery agent that facilitates effective delivery of drugs and other compounds across lipid layers. The delivery agent disclosed herein provides lipid solubility under selected conditions and aqueous solubility under other conditions, and can effectively deliver compounds into the cell cytosol. The disclosed delivery agent also avoids deleterious interactions with serum and thus provide efficient in vivo delivery of therapeutic agents.
Owner:ENDOREL BIOSCIENCES LLC

Yeast having high rubisco carboxylase activity and method for constructing the same

This invention aims to create a spatially isolated local reaction microenvironment for Rubisco by introducing a complete β-carboxysome microcompartment system. This design goal avoids oxygen inhibition, laying the foundation for ultimately achieving efficient and specific CO2 fixation. It provides a novel approach to overcome the fundamental problem of low efficiency of carbon-fixing enzymes in cytosols due to intense oxygen competition. By introducing the complete carboxysome system as a module, engineered yeast strains with high carboxylase activity and significantly improved ethanol production were obtained, providing a solid foundation for building next-generation yeast cell factories that produce high-yield ethanol using CO2 as a raw material.
Owner:HUAZHONG AGRI UNIV

Targeting and localized in vivo delivery of oligonucleotides

This invention provides targeted conjugates and methods that improve the targeting and local in vivo delivery of oligonucleotides. [Solution] A composition containing a targeted oligonucleotide-HES conjugate is provided as a method for constructing and using the conjugate in therapeutic, diagnostic, and other applications. The oligonucleotide-HES complex contained in the targeted oligonucleotide-HES conjugate can cross membranes in a receptor-independent manner and can deliver oligonucleotides containing complementary sequences to the cytosol of living cells in vivo. The targeted oligonucleotide-HES conjugate has uses including the targeting and / or local delivery of antisense oligonucleotides, siRNAs, shRNAs, Dicer substrates, miRNAs, anti-miRNAs, and other nucleic acid sequences in living organisms.
Owner:ONCOIMMUNIN INC

E. coli strains having an oxidative cytoplasm

PendingUS20260078337A1BacteriaTransferasesDisulfide bondingThioredoxin-1
This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.
Owner:SUTRO BIOPHARMA INC

Mitochondrial optogenetics-based gene therapies and their methods of use

PCT designated stageWO2026112440A1Peptide/protein ingredientsMicroencapsulation basedInner mitochondrial membraneNucleic acid sequence
The present disclosure is directed to compositions comprising mitochondrial optogenetics-based gene therapies and their methods of use. In some embodiments, a composition described herein comprises an expression vector comprising a first nucleic acid sequence encoding a channelrhodopsin fusion protein and a second nucleic acid sequence encoding a luciferase protein. In some cases, the first nucleic acid sequence and the second nucleic acid sequence are operably linked to an expression control sequence. In some instances, the channelrhodopsin fusion protein comprises a channelrhodopsin protein linked to an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS). In some implementations, when the expression vector is expressed, the luciferase protein is localized to the cytosol. In some cases, the IMM-MLS comprises a leading sequence from a mitochondrial inner membrane protein selected from ABCB10, ABCB140, Cytochrome C, and renal outer medullary potassium channel (ROMK).
Owner:OHIO STATE INNOVATION FOUND

Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition

The invention relates to a conjugate for transferring an effector molecule from outside a cell into said cell, the conjugate comprising at least one effector molecule to be transferred into the cell, at least one saponin of the mono-desmosidic triterpene glycoside type or the bi-desmosidic triterpene glycoside type, and at least one single-domain antibody (sdAb), covalently bound to each other, wherein the sdAb is capable of binding to a cell-surface molecule of said cell. The invention also relates to a pharmaceutical composition comprising the conjugate of the invention. Furthermore, the invention relates to a pharmaceutical composition of the invention, for use as a medicament. In addition, the invention relates to a pharmaceutical composition of the invention, for use in the treatment or the prophylaxis of any one or more of: a cancer, an auto-immune disease such as rheumatoid arthritis, an enzyme deficiency, a disease related to an enzyme deficiency, a gene defect, a disease relating to a gene defect, an infection such as a viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, an amyloidosis and transthyretin-mediated amyloidosis. The invention also relates to an in vitro or ex vivo method for transferring the conjugate from outside a cell to inside said cell or for transferring the effector molecule comprised by the conjugate of the invention from outside a cell to inside said cell, preferably to the cytosol of said cell.
Owner:SAPREME TECH BV

Compositions and methods for cell-based assays

Compositions and methods for characterization binding proteins are described that include use of a reporting construct that incorporates a bait region that interacts with the binding protein and a reporter that is susceptible to degradation in the reporter's local environment. Complex formation between the bait region and the binding protein provides protection of the susceptible reporter from degradation. Such a reporting construct can be utilized to identify cells expressing a binding protein when the susceptible reporter is susceptible to degradation in cytosol.
Owner:BIOMADISON INC

Novel anthelmintic cry proteins and uses thereof

Compositions and methods for treating or reducing the severity or likelihood of occurrence of a parasitic worm infection in a human, an animal, or a plant are described. Compositions including isolated, native, bioactive crystals of CryH1 or CryH13 and inactivated or live recombinant bacteria expressing a CryH1 or CryH13 crystal proteins in the cytosol of the bacterium are described. Compositions suitable for pharmaceutical and agricultural applications are provided. Methods of administering a therapeutically effective amount of a composition to a human or animal suffering from a parasitic worm infection are provided. Compositions are provided for use as animal feed, feed supplement, or in waste treatment. Methods of agricultural applications for control of parasitic worm infections are provided.
Owner:UNIV OF MASSACHUSETTS +1

Gram-positive bacterium extracellular electron transport chain construction method and synthetic microbial agent

The invention discloses a gram-positive bacterium extracellular electron transport chain construction method and a synthetic microbial agent. It is found that after a lipophilic material is added into an iron reduction system, the iron reduction speed and the iron reduction amount of gram-positive bacteria with weak electron transfer capacity are remarkably increased, and the iron reduction amount of the gram-positive bacteria can be consistent with the iron reduction magnitude of gram-negative strong iron reduction bacteria. The lipophilic degree and the iron reduction rate are subjected to correlation analysis and show significant positive correlation, which reveals that the lipophilic degree and the permeable membrane capacity of the material are key parameters for determining the iron reduction capacity of gram-positive bacteria. The lipophilic material not only can smoothly penetrate through the cell wall of gram-positive bacteria, but also can be enriched on a cell membrane in quantity, and gradually permeates into a cytoplasm matrix to generate electron exchange with NADH (Nicotinamide Adenine Dinucleotide Hormone) so as to construct a gram-positive bacteria extracellular electron transport chain. The invention provides a brand-new strategy for preparing the biological geological catalytic synthetic microbial inoculum for soil iron reduction.
Owner:GUANGDONG INST OF ECO ENVIRONMENT & SOIL SCI

Novel technology to enable sucrose utilization in strains for biosynthetic production

The present disclosure relates to a genetically modified cell capable of utilizing sucrose as energy and carbon source following the expression of a single heterologous enzyme, which upon expression is translocated from the cytosol and which is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose.The identification of efficient enzymes capable of hydrolysing sucrose in its non-modified form, and which on its own enable the cell to utilize sucrose as a, or as the main and / or sole, carbon and / or energy source, i.e., without the need for multi-gene sucrose utilizing systems comprising several other heterologous polypeptides, such as other enzymes and / or transporters, is highly advantageous, since it allows for cost-effective use of sucrose in large scale production processes.
Owner:DSM IP ASSETS BV

Compositions and methods for the treatment of actinomycetia infections

The present disclosure features compositions and methods for the treatment of actinomycetia (e.g., corynebacteriales) infections, e.g., caused by mycobacterial cells, residing within a host cell (e.g., a mammalian cell, e.g., immune cell, e.g., macrophage or dendritic cell). The compositions and methods include delivering a mixture of lytic enzymes to specifically target the cell envelope of a group of related bacterial species in the intracellular compartment (endosome, phagosome, lysosome, or cytosol) in which above mentioned orders of bacteria infect, grow, hide, and go quiescent.
Owner:ENDOLYTIX TECHNOLOGY INC

Methods for increasing plant growth using phytoinitiator mRNAs in plant cells

The invention relates to a method for increasing plant growth by administering phytoinitiator mRNAs obtained from seedling chloroplasts. The mRNAs can either be translated directly into chloroplasts or first translated in the cytosol and subsequently imported into the chloroplasts as proteins. In both cases, the resulting proteins lead to the activation of hormonal signaling pathways, increased protein synthesis, and a significant increase in root biomass, shoot number, and hypocotyl growth. The invention further comprises formulations and application systems such as granules, sprays, or injections that enable efficient uptake and action of the mRNAs.
Owner:PHYTOAR BIOTECHNOLOGIE GMBH

Treatment method

To provide a method and a composition for delivering a nucleic acid to a cell or a cytosol of a target cell.SOLUTION: A method includes bringing a cell in contact with 1) a membrane-destabilizing polymer and 2) a nucleic acid complex. The nucleic acid complex includes an optionally selected linker and a target-directional ligand bonded to a nucleic acid.SELECTED DRAWING: None
Owner:GENEVANT SCI GMBH

A lightGBM-based lncRNA subcellular localization prediction method

The application discloses a kind of lncRNA subcellular localization prediction method based on lightGBM, comprising, first, the nucleotide of the front section multiple of known lncRNA sequence is intercepted as sequence sample one;Then by based on single strand multiclass position-specific three nucleotide bias and reverse complementary kmer, sequence sample one is respectively characterized coding, the combination of two kinds of feature coding is vector;Use lightGMB as learning algorithm;Using 5-fold cross validation optimization reverse complementary kmer and LightGBM's hyperparameter;Most intercept unknown lncRNA sequence front end multiple bases as sequence sample two, and its single strand multiclass position-specific three nucleotide bias and the combination of optimized reverse complementary kmer feature coding is input in trained lightGBM, will obtain its localization subcellular type, the patent of the application can be according to long-chain non-coding RNA sequence prediction in cytoplasm, nucleus, ribosome, cytosol, exosome five subcellular positions, the application realizes simply, and prediction precision is high.
Owner:HUNAN UNIV OF FINANCE & ECONOMICS

Method for increasing plant growth using phyto-initiator mrnas in plant cells

PCT designated stageWO2026082763A1Plant phenotype modificationBiotechnologyHypocotyl
The invention relates to a method for increasing plant growth by delivering phyto-initiator mRNAs derived from chloroplasts of seedlings. The mRNAs may either be translated directly in chloroplasts or first translated in the cytosol and subsequently imported into the chloroplasts in the form of proteins. In both cases, the resulting proteins activate hormonal signalling pathways, increased protein synthesis, and bring about a significant enhancement of root biomass, shoot number and hypocotyl growth. The invention also relates to formulations and application systems such as granules, sprays or injections which enable efficient uptake and activity of the mRNAs.
Owner:PHYTOAR BIOTECHNOLOGIE GMBH

Microbial strain expressing an invertase / sucrose hydrolase

The present disclosure relates to a genetically modified cell capable of utilizing sucrose as energy and carbon source following the expression of a single heterologous enzyme, which upon expression is translocated from the cytosol and which is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose.The identification of efficient enzymes capable of hydrolysing sucrose in its non-modified form, and which on its own enable the cell to utilize sucrose as a, or as the main and / or sole, carbon and / or energy source, i.e., without the need for multi-gene sucrose utilizing systems comprising several other heterologous polypeptides, such as other enzymes and / or transporters, is highly advantageous, since it allows for cost-effective use of sucrose in large scale production processes.
Owner:DSM IP ASSETS BV

A therapeutic nucleic acid-encased nanoworm for gene delivery and endosomal escape

PCT designated stage expiredWO2025077898A1Organic active ingredientsGold compoundsGene deliveryDisease
An effective and safe composition comprises an anionic gold-polydopamine core-shell nanoworm as an alternative gene carrier for bypassing the bottleneck of endosomal entrapment. The nanoworm can be used in methods of delivering therapeutic oligonucleotides to a subject. A polydopamine shell supports the surface adsorption of nucleic acids. The anionic nucleic acid-encased nanoworm can then enter cells without transfection agents and activate the ClC3 H + / Cl - exchanger in late endosomes to mediate vesicular accumulation of H + and Cl -, which causes membrane rupture, and finally escape to cytosol without cell-penetrating peptides or mechanical stimuli. The nanoworm can be further used for programming cellular responses, i. e., primary macrophage polarization and stem cell differentiation, for the treatment of diseases, such as kidney fibrosis and acute liver injury.
Owner:THE CHINESE UNIVERSITY OF HONG KONG

Compositions Comprising Therapeutic Nucleic Acids and Targeted Saponins for the Treatment of Muscle Wasting Disorders

The present invention relates to the field of treatment and prevention of muscle wasting disorders, in particular those involving genetic factors that can be targeted by delivery of therapeutic nucleic acids to muscle cells. In keeping with the latter aspect, pharmaceutical compositions and advantageous components thereof are disclosed that substantially facilitate effective delivery and release of therapeutic nucleic acids to the correct intracellular compartments of muscle cells, such as the cytosol and / or nucleus, where the therapeutic nucleic acid can reach and act on its genetic target. As disclosed herein, this substantial enhancement of delivery and release is achieved by providing a pharmaceutical composition comprising a therapeutic nucleic acid with an endosomal escape-promoting saponin that is specifically targeted to muscle cells by covalent conjugation with a ligand of an endocytic receptor present on the muscle cell. As demonstrated for the first time herein, this type of saponin surprisingly retains its endosomal escape-promoting properties in fully differentiated muscle cells.
Owner:SAPREME TECH BV

Targeted saponin-nucleic acid conjugates for the treatment of muscle wasting disorders

The present invention relates to the field of treatment and prevention of muscle wasting disorders, in particular those involving genetic factors that can be targeted by delivery of therapeutic nucleic acids to muscle cells. With the latter aspect in mind, herein disclosed are pharmaceutical compositions and advantageous components thereof that substantially facilitate effective delivery and release of therapeutic nucleic acids to the correct intracellular compartments of muscle cells, such as the cytosol and / or nucleus, where the therapeutic nucleic acid can reach and act on its genetic target. As disclosed herein, this substantial enhancement of delivery and release is achieved by providing an endosomal escape-promoting saponin in the pharmaceutical composition disclosed herein, comprising a therapeutic nucleic acid and a muscle cell targeting ligand. As demonstrated for the first time herein, this type of saponin surprisingly not only retains its endosomal escape-promoting properties in fully differentiated muscle cells, but also appears to successfully reach and enter muscle cells in vivo via an endothelial transcytosis pathway and subsequent endocytic trapping in the sarcolemma.
Owner:SAPREME TECH BV

Cutting filter screen and cell matrix separation device

The cutting filter screen comprises a filter screen outer frame and a plurality of separators arranged in the filter screen outer frame, filter holes are formed among the separators, at least two filter holes with different and regular shapes are formed in the surface of the cutting filter screen, and a zigzag structure for cutting a cell matrix is arranged in the filter hole with at least one shape. The zigzag structure can form a cutting edge in the through hole in the filtering direction. Compared with the prior art, by means of the zigzag structures arranged in the filter holes in the cutting filter screen, when the cell matrix enters the sleeving shell and penetrates through the cutting filter screen, the cytoplasm matrix can be destroyed through the cutting edges formed by the zigzag structures, and due to the fact that the cutting edges of the cutting edges are formed in the filtering direction, the cell matrix can be conveniently cut. And the cell matrix can pass through smoothly, so that an operator can control the cell matrix to quickly penetrate through the filter screen in a reciprocating manner more conveniently, and the cutting efficiency is improved.
Owner:JUNWEI FANGCHENG (WUHAN) MEDICAL TECHNOLOGY SERVICE CO LTD

Cell compositions and related methods

This invention relates to erythroid cells, such as reticulocyte cells, engineered to express a variant protein which comprises one or more mutations which increase the level of the variant protein in the cytosol of the cells. The invention also relates to erythroid cells, such as reticulocyte cells, genetically engineered to overexpress antioxidant proteins and / or an intrinsically disordered proteins (IDPs) in their cytosol and variants of such proteins which facilitate their overexpression in the cytosol of cells. Modification of the cells in this way enhances their storage, whether by refrigeration, freezing, lyophilisation or another storage method. The cells of the invention can be used to deliver therapeutic proteins or polypeptides.
Owner:UNIV OF BRISTOL

Compositions and methods for treating actinomycete infections

The present disclosure features compositions and methods for the treatment of actinomycete (e.g., Corynebacteriales) infections caused by mycobacterial cells residing within a host cell (e.g., a mammalian cell, such as an immune cell, e.g., a macrophage or dendritic cell). The compositions and methods involve delivering a mixture of lytic enzymes to specifically target the cell envelope of a group of related bacterial species within intracellular compartments (endosomes, phagosomes, lysosomes, or cytosol) where bacteria of the aforementioned orders infect, grow, hide, and rest.
Owner:ENDOLYTIX TECHNOLOGY INC

Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders

The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line with the latter aspect, disclosed herein are pharmaceutical compositions and advantageous components thereof that substantially enhance the effective delivery and release of a therapeutic nucleic acid into the correct internal compartment of the muscle cell, such as the cytosol and / or the nucleus, in which compartment it can reach and act upon its genetic target. As disclosed herein, this substantially enhanced delivery and release is achieved by a provision of an endosomal-escape-enhancing saponin in the disclosed herein pharmaceutical compositions comprising therapeutic nucleic acids and muscle cell-targeting ligands. As for the first time demonstrated herein, these saponin types surprisingly not only appear to retain their endosomal-escape-enhancing properties in fully differentiated muscle cells, but also successfully reach and enter muscle cells in vivo through endothelial transcytosis route followed by endocytic capture at the sarcolemma.
Owner:SAPREME TECH BV

Skin-like chip simulation platform based on microfluidic technology

The invention relates to a skin-like chip simulation platform based on a microfluidic technology. The skin-like chip simulation platform sequentially comprises a skin-like layer, a skin-like layer, a cytoplasm matrix simulation layer and an interstitial fluid circulation layer from top to bottom, a hole array is arranged on the imitated skin layer; an interstitial fluid enrichment cavity communicated with the hole array is formed in the simulated cortex, and the interstitial fluid enrichment cavity is provided with an enrichment outlet and an enrichment inlet; an interstitial fluid micro-channel is arranged in the cytoplasm matrix simulation layer, one end of the interstitial fluid micro-channel is communicated to the enrichment inlet, and the other end of the interstitial fluid micro-channel is communicated to the interstitial fluid flowing layer; an interstitial fluid storage cavity is formed in the interstitial fluid circulation layer and is provided with a storage cavity outlet and a storage cavity inlet; the device further comprises an interstitial fluid circulation channel. The skin-like chip simulation platform designed by the invention can accurately simulate the human skin environment, provides a simulation test platform for novel extraction electrode design, parameter optimization and safety evaluation of a counter ion electroosmosis technology, and remarkably reduces the preclinical research risk and cost of new technology development.
Owner:XIAN JIAOTONG LIVERPOOL UNIV

Antagonist of the mirna-106b-5p to treat or prevent the cardiotoxicity that is developed in oncologic patients after receiving anthracycline-based chemotherapy

It is herein demonstrated that an increase in Dox-induced miRNA-106b-5p (miR-106b) is able to down-regulate PR55α subunit, which leds to a decrease both in PP2A activity as well as an accumulation of the phosphorylated HDAC4 protein in cytosol. Anti-miRNA-106b-5p (miR-106b) therapy is thus able to prevent Dox-induced PR55α degradation, facilitate the HDAC4 dephosphorylation by PP2A, and increase HDAC4-YY1 interaction, resulting in a decreased in sST2 expression and release by the LV myocardium. Further, and for first time, it has identified the role that sST2 isoform plays in Dox-induced CTX.
Owner:UNIVERSITY OF MURCIA

Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and / or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same

The present description relates to methods for delivering polypeptide cargos from an extracellular space to the cytosol and / or nucleus of a target eukaryotic cell. The methods involve contacting the cell with the polypeptide cargo in the presence of a peptide shuttle agent at a concentration sufficient to increase the polypeptide cargo's transduction efficiency. Also described here are parameters that may be used in the rational design of such synthetic peptide shuttle agents, peptide shuttle agents that satisfy one or more of these design parameters, as well as methods and compositions relating to the use of the synthetic peptide shuttle agents for delivery of a variety of polypeptide cargos (such as transcription factors, antibodies, CRISPR-associated nucleases and functional genome editing complexes) from an extracellular space to the cytosol and / or nucleus of target eukaryotic cells. Applications and targets for genome-editing NK cells for improved immunotherapy are also described.
Owner:FELDAN BIO INC